If it is true that pimozide is functioning as a STAT5 inhibitor downstream from BCR/ABL, then it would be expected that pimozide would be equally efficacious in inhibiting the viability of CML cells even in the presence of mutations in BCR/ABL that render them resistant to kinase inhibitors. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.